Reading the tape
NASDAQ: GERN
Geron Corporation
Healthcare · Biotechnology
Market Cap
$1.01B
52w High
$2.01
52w Low
$1.04
P/E
-12.21
Volume
9.69M
Outstanding Shares
640.90M
Price vs Fundamentals
Why The Stock Is Moving
Mixed / unclearLow confidence
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
1Y Price: 10.56%Revenue (TTM): 138.83%FCF (TTM): 49.33%P/S: 20th pct
What changed
The stock rose 10.56% over the last year. Revenue grew 138.83% over the trailing twelve months. Operating margin moved from -225.64% to -29.28%. Free cash flow grew 49.33% over the trailing twelve months.
What the market seems to be pricing
The stock has moved higher against modestly improving underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.
What would invalidate this read
Operating margin currently stands at -29.28%. A decisive move in revenue — currently up 138.83% — would be the clearest signal to resolve the ambiguity.
Company profile
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies.
CEOHarout Semerjian
SectorHealthcare
IndustryBiotechnology
Employees229
IPO dateJul 31, 1996
Valuation
Forward P/E—
EV/EBITDA-20.26
Enterprise value$1.05B
Stock splits
Jul 22, 2014↑ Forward
Every 500 shares became 529
Profitability & growth
Revenue growth1.01%
Gross margin85.96%▼0.96%vs FY2024
Operating margin-29.28%▲87.03%vs FY2024
ROE-37.98%▲39.02%vs FY2024
Analyst consensus
RatingBuy
Target price$5.89▲275.16%
17
Buy
5
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
May 6, 2026
Q2 FY26 · EPS est -$0.03 · Revenue est $50.59M
View